PL2761065T3 - Kompozycje i sposoby do testów toksykogenności - Google Patents

Kompozycje i sposoby do testów toksykogenności

Info

Publication number
PL2761065T3
PL2761065T3 PL12835606T PL12835606T PL2761065T3 PL 2761065 T3 PL2761065 T3 PL 2761065T3 PL 12835606 T PL12835606 T PL 12835606T PL 12835606 T PL12835606 T PL 12835606T PL 2761065 T3 PL2761065 T3 PL 2761065T3
Authority
PL
Poland
Prior art keywords
compositions
methods
toxigenicity
testing
toxigenicity testing
Prior art date
Application number
PL12835606T
Other languages
English (en)
Inventor
Regina Clare Meyer Whitemarsh
Eric Arthur Johnson
Sabine Pellett
William Howard Tepp
Original Assignee
Cellsnap, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellsnap, Llc filed Critical Cellsnap, Llc
Publication of PL2761065T3 publication Critical patent/PL2761065T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073Stem cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
PL12835606T 2011-09-29 2012-09-28 Kompozycje i sposoby do testów toksykogenności PL2761065T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161540693P 2011-09-29 2011-09-29
PCT/US2012/057825 WO2013049508A1 (en) 2011-09-29 2012-09-28 Compositions and methods for toxigenicity testing
EP12835606.0A EP2761065B1 (en) 2011-09-29 2012-09-28 Compositions and methods for toxigenicity testing

Publications (1)

Publication Number Publication Date
PL2761065T3 true PL2761065T3 (pl) 2018-02-28

Family

ID=47996425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12835606T PL2761065T3 (pl) 2011-09-29 2012-09-28 Kompozycje i sposoby do testów toksykogenności

Country Status (19)

Country Link
US (1) US9217172B2 (pl)
EP (1) EP2761065B1 (pl)
JP (1) JP5877617B2 (pl)
KR (1) KR101640694B1 (pl)
CN (1) CN103958747B (pl)
AU (1) AU2012315783B2 (pl)
BR (1) BR112014007717B1 (pl)
CA (1) CA2850531C (pl)
ES (1) ES2653249T3 (pl)
HR (1) HRP20171937T1 (pl)
HU (1) HUE037509T2 (pl)
IL (1) IL231768B (pl)
LT (1) LT2761065T (pl)
MX (1) MX348188B (pl)
PL (1) PL2761065T3 (pl)
RU (1) RU2616281C2 (pl)
SG (1) SG11201401007SA (pl)
SI (1) SI2761065T1 (pl)
WO (1) WO2013049508A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3014267B1 (en) 2013-06-28 2018-11-07 Merz Pharma GmbH & Co. KGaA Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
EP3270162B2 (en) 2013-08-09 2023-08-16 BioMadison, Inc. Botulinum toxin assay with improved sensitivity
EP2952205B1 (en) 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
TWI669129B (zh) 2014-12-23 2019-08-21 德商梅茲製藥有限兩合公司 預填充式玻璃容器及其套組與使用
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
WO2017148915A1 (en) 2016-03-02 2017-09-08 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
SI3463432T1 (sl) 2016-05-27 2021-02-26 Ipsen Biopharm Limited Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
KR20240160669A (ko) 2017-03-24 2024-11-11 메르츠 파마 게엠베하 운트 코. 카가아 타액과다증의 치료에서의 보툴리늄 신경독소의 개선된 용도
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019081022A1 (en) 2017-10-26 2019-05-02 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH INCREASED DURATION
EP3713595A1 (en) 2017-11-22 2020-09-30 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with increased duration of effect
EP3856923A1 (en) * 2018-09-28 2021-08-04 Ipsen Biopharm Limited Cell-based clostridal neurotoxin assays
US20210393748A1 (en) 2018-10-02 2021-12-23 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for treating lipoedema
WO2020074419A1 (en) 2018-10-08 2020-04-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxin prefilled vial
BR112021015480A2 (pt) 2019-02-21 2021-10-05 Merz Pharma Gmbh & Co. Kgaa Usos inovadores de neurotoxina botulínica para o tratamento contra tremor
KR102297991B1 (ko) * 2019-10-11 2021-09-07 주식회사 하울바이오 SNARE 복합체를 억제하는 항-Syntaxin 1A 항체 및 이의 용도
AU2021286196A1 (en) 2020-06-05 2022-12-01 Merz Pharma Gmbh & Co. Kgaa High dose and low volume botulinum toxin treatment of facial wrinkles
US20220010355A1 (en) * 2020-07-10 2022-01-13 Galderma Holding SA Cell based method for determination of botulinum toxin potency based on western blotting
CN113774023B (zh) * 2021-09-28 2022-11-25 中国食品药品检定研究院 人诱导多能干细胞诱导分化神经细胞评价模型的构建及其评价药物神经毒性的用途
AU2023207838A1 (en) 2022-01-14 2024-07-04 Galderma Holding SA Treatment of moderate to very severe glabellar lines and lateral canthal lines
KR20240141340A (ko) 2022-02-15 2024-09-26 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 액체 제형 및 그 용도
IL314995A (en) 2022-02-15 2024-10-01 Merz Pharma Gmbh & Co Kgaa Liquid botulinum toxin formulation and use thereof
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及/或皮脂產生之用途、以及降低皮膚毛孔尺寸及/或皮脂產生的方法
IL320937A (en) 2022-11-28 2025-07-01 Merz Pharma Gmbh & Co Kgaa High-concentration botulinum toxin treatment for neck rejuvenation
WO2024115412A1 (en) 2022-11-28 2024-06-06 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin injection in platysma for lower face and neck rejuvenation
CN120225172A (zh) 2022-12-15 2025-06-27 莫茨药物股份两合公司 包含肉毒杆菌毒素的可注射凝胶及其用途
WO2024189148A1 (en) 2023-03-15 2024-09-19 Merz Pharma Gmbh & Co. Kgaa A rocking shaker for treating at least one fluid sample
WO2024194181A1 (en) 2023-03-20 2024-09-26 Merz Therapeutics GmbH Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient
WO2024240868A1 (en) 2023-05-23 2024-11-28 Merz Therapeutics GmbH Botulinum toxin for treating peripheral neuropathic pain
WO2025012403A1 (en) 2023-07-12 2025-01-16 Merz Pharma Gmbh & Co. Kgaa Treatment of hyperpigmentation conditions by botulinum toxin
WO2025032220A1 (en) 2023-08-10 2025-02-13 Merz Pharma Gmbh & Co. Kgaa Liquid botulinum toxin formulation and use thereof
CN117887797B (zh) * 2023-12-27 2024-09-20 中国食品药品检定研究院 一种梭状芽胞杆菌神经毒素效价检测方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
TR200000181T2 (tr) * 1997-07-21 2000-05-22 Arpi Matossian-Rogers Antikorların dahil olduğu, endokrin hücrelerine karşı aktivite gösteren ligandlar.
US7115399B2 (en) 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US6984375B2 (en) 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
GB2398636A (en) 2003-02-21 2004-08-25 Ipsen Ltd Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample
EP2332959B1 (en) 2003-12-19 2014-11-26 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
CA2558758C (en) * 2004-02-24 2015-06-23 Allergan, Inc. Botulinum toxin screening assays
GB2416849A (en) 2004-08-04 2006-02-08 Ipsen Ltd Method for determining the quantity of a pre-synaptic neuromuscular blocking substance in a sample
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2341892T5 (es) 2005-09-19 2019-03-27 Allergan Inc Toxina clostridial activable por toxinas clostridiales
EP2015065B1 (en) 2006-04-28 2011-10-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method of quantifying neurotoxin
US8067192B2 (en) * 2007-06-05 2011-11-29 City Of Hope Methods for detection of botulinum neurotoxin
US8609413B2 (en) * 2007-12-11 2013-12-17 Research Development Foundation Neurons, astrocytes and oligodendrocytes differentiated from a mammalian pluripotent or neural stem cells exposed to a pyridine deriviative
EP3095470A1 (en) * 2008-02-07 2016-11-23 Shahar Cohen Compartmental extract compositions for tissue engineering
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
WO2010008486A2 (en) * 2008-06-24 2010-01-21 Parkinsons Institute Pluripotent cell lines and methods of use thereof
EP2191847A1 (en) * 2008-11-19 2010-06-02 Merz Pharma GmbH & Co.KGaA Method for preparing compositions comprising a protein, water and glycerol
CA2753208C (en) * 2009-02-20 2018-08-21 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
KR101720961B1 (ko) * 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
SI2406371T1 (sl) 2009-03-13 2018-10-30 Allergan, Inc. Celice, koristne za teste aktivnosti botulinskega toksina serotipa a na podlagi imunologije
US8420352B2 (en) * 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
JP5885255B2 (ja) 2009-08-28 2016-03-15 セルラー ダイナミクス インターナショナル, インコーポレイテッド 罹患組織における遺伝的変異の同定
EP2496689B1 (en) 2009-11-04 2015-05-20 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
WO2012123370A1 (en) 2011-03-11 2012-09-20 Merz Pharma Gmbh & Co. Kgaa Method for the determination of botulinum neurotoxin biological activity
JP6185907B2 (ja) 2011-03-30 2017-08-23 セルラー ダイナミクス インターナショナル, インコーポレイテッド 神経分化のための多能性幹細胞の予備刺激
US10451621B2 (en) * 2011-12-31 2019-10-22 Allergan, Inc. Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
EP2823053B1 (en) * 2012-03-07 2017-08-23 Merz Pharma GmbH & Co. KGaA Means and methods for determining neurotoxin activity based on a modified luciferase
US8778623B2 (en) * 2012-09-14 2014-07-15 Wisconsin Alumni Research Foundation Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin
US9102901B2 (en) * 2012-12-20 2015-08-11 Rohm And Haas Electronic Materials Llc Methods and compositions for removal of metal hardmasks

Also Published As

Publication number Publication date
SI2761065T1 (en) 2018-02-28
EP2761065A1 (en) 2014-08-06
HRP20171937T1 (hr) 2018-02-09
CN103958747B (zh) 2017-03-01
HUE037509T2 (hu) 2018-09-28
RU2014117161A (ru) 2015-11-10
HK1199911A1 (en) 2015-07-24
IL231768B (en) 2019-06-30
ES2653249T3 (es) 2018-02-06
CN103958747A (zh) 2014-07-30
BR112014007717A2 (pt) 2017-04-25
AU2012315783B2 (en) 2015-08-20
RU2616281C2 (ru) 2017-04-13
KR101640694B1 (ko) 2016-07-18
US9217172B2 (en) 2015-12-22
KR20140086981A (ko) 2014-07-08
BR112014007717B1 (pt) 2021-07-20
CA2850531A1 (en) 2013-04-04
JP2014528724A (ja) 2014-10-30
IL231768A0 (en) 2014-05-28
WO2013049508A1 (en) 2013-04-04
JP5877617B2 (ja) 2016-03-08
US20140234857A1 (en) 2014-08-21
MX2014003874A (es) 2014-08-18
LT2761065T (lt) 2018-01-10
EP2761065A4 (en) 2015-05-06
SG11201401007SA (en) 2014-04-28
AU2012315783A1 (en) 2014-04-17
EP2761065B1 (en) 2017-12-06
CA2850531C (en) 2016-06-07
MX348188B (es) 2017-06-01

Similar Documents

Publication Publication Date Title
IL231768B (en) Preparations and methods for testing toxicity
ZA201502880B (en) Compositions and methods for immunotherapy
IL224390B (en) Compositions and methods for targeted thermal modulation
EP2742154A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2721179A4 (en) BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
PT2731451T (pt) Métodos e composições para produtos de consumo
ZA201306316B (en) Methods and compositions for preparing noribogaine from voacangine
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
IL231131A0 (en) Methods and preparations for determining smoking status
ZA201404187B (en) Compositions and methods for treating dental conditions
ZA201307187B (en) Synergistic compositions and methods
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL232648A0 (en) Preparations and methods for treating glioma
GB201411762D0 (en) Precoating methods and compositions
ZA201308892B (en) Compositions and methods
EP2734646A4 (en) COMPOSITIONS AND METHODS FOR SELECTING APTAMERS
EP2798327A4 (en) COMPOSITIONS AND METHODS FOR PREPARING SAMPLES
EP2665480A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM
SMT202100100T1 (it) Metodi e composizioni per inibire una patologia associata a polyomavirus
GB201116340D0 (en) Compositions and methods
IL230868A0 (en) Biomarker preparations and methods
GB201122124D0 (en) Compositions and methods for treating biofilms
GB201104584D0 (en) Compositions and methods for treating biofilms
IL228723B (en) Synergistic compositions and methods
GB201100831D0 (en) Apparatus method and compositions